Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.81 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.81 |
| ▸ | ME2 | P23368 | 1/20 | 0.64 |
| ▸ | ME1 | P48163 | 1/20 | 0.64 |
| ▸ | ME3 | Q16798 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.51 |
| ▸ | GALK1 | P51570 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL5721 | 0.90 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293211 | 0.90 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL446833 | 0.90 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293206 | 0.90 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL29362189 | 0.90 | GPR35 (1.00) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5379175 | 0.88 | GPR35 (0.91) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL15955719 | 0.88 | GPR35 (0.91) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014428 | 0.88 | GPR35 (0.97) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5014030 | 0.88 | GPR35 (0.97) | POLBGPR35ME2ME1ME3 | |
| Pamoic Acid SCHEMBL5012888 | 0.88 | GPR35 (0.97) | POLBGPR35ME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8980880-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8957067-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8940729-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8916587-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8912217-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8716278-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716337-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8653065-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653106-B2 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8586575-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | PISGAH LABORATORIES, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | COMT, SLC6A3, SLC6A2 | POLB 2001/4885GPR35 427/4885ME2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.